Ballentine Partners, LLC Biogen Inc. Transaction History
Ballentine Partners, LLC
- $5.25 Billion
- Q1 2024
A detailed history of Ballentine Partners, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 1,667 shares of BIIB stock, worth $377,408. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,667
Previous 1,649
1.09%
Holding current value
$377,408
Previous $426,000
15.73%
% of portfolio
0.01%
Previous 0.01%
Shares
27 transactions
Others Institutions Holding BIIB
# of Institutions
1,046Shares Held
126MCall Options Held
1.37MPut Options Held
1.35M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.75 Billion0.07% of portfolio
-
Primecap Management CO Pasadena, CA16.2MShares$3.67 Billion2.65% of portfolio
-
Black Rock Inc. New York, NY14.1MShares$3.2 Billion0.07% of portfolio
-
State Street Corp Boston, MA6.75MShares$1.53 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.17MShares$1.17 Billion0.68% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $32.6B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...